摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-叔丁氧羰基-D-3-硝基苯丙氨酸 | 158741-21-0

中文名称
N-叔丁氧羰基-D-3-硝基苯丙氨酸
中文别名
Boc-3-硝基-D-苯丙氨酸;Boc-D-3-硝基苯丙氨酸;叔丁氧羰基-D-3-硝基苯丙氨酸;N-叔丁氧羰基-D-3-硝基苯丙氨酸;叔丁氧羰基-D-3-硝基苯丙氨酸;BOC-3-硝基-D-苯丙氨酸
英文名称
D-N-Boc-3-nitrophenylalanine
英文别名
Boc-D-3-nitrophenylalanine;Boc-3-Nitro-D-phenylalanine;(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(3-nitrophenyl)propanoic acid
N-叔丁氧羰基-D-3-硝基苯丙氨酸化学式
CAS
158741-21-0
化学式
C14H18N2O6
mdl
——
分子量
310.307
InChiKey
OWTGPXDXLMNQKK-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    506.9±45.0 °C(Predicted)
  • 密度:
    1.290±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    121
  • 氢给体数:
    2
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2924299090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
  • 危险性描述:
    H302,H312,H332

SDS

SDS:a8dc222aac6183bd1c5a2a458623be8c
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Boc-D-3-nitrophenylalanine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Boc-D-3-nitrophenylalanine
CAS number: 158741-21-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H18N2O6
Molecular weight: 310.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-叔丁氧羰基-D-3-硝基苯丙氨酸 在 palladium on activated charcoal 氢气溶剂黄146 作用下, 以 乙醇 为溶剂, 以68%的产率得到D-N-Boc-3-aminophenylalanine
    参考文献:
    名称:
    Gonadotropin-Releasing Hormone Antagonists: Novel Members of the Azaline B Family
    摘要:
    A series of antagonists of gonadotropin-releasing hormone (GnRH) homologous to azaline B ([Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Atz),ILys(8),DAla(10)]GnRH) was synthesized, characterized, and tested in a rat antiovulatory assay (AOA). Selected analogues were also tested in both an in vitro dispersed rat pituitary cell culture assay for inhibition of GnRH-stimulated luteinizing hormone release and an in. vitro histamine release assay. The duration of action of some of the most potent and safest analogues in those assays was also determined in the castrated male rat in order to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone release. Structurally, this series of analogues has novel substitutions (X and Y) in the structure of the azaline B precursor: [Ac-DNal(1),DCpa(2),DPal(3),-Aph(5)(X),DAph(6)(Y),ILys(8),DAla(10)]GnRH. These substitutions were designed to confer increased hydrophilicity as compared to that of azaline B (determined by relative retention times on a C-18 reverse phase column using a triethylammonium phosphate buffer at pH 7.3) or to make them more easily accessible synthetically. Some bulky substituents were introduced in order to probe the spatial limitations of the receptor's cavity. These substitutions include acylated 4-aminophenylalanine at positions 5 and/or 6 (29 analogues), N-alpha-methylated backbone substitutions (six analogues), N-omega-isopropylaminophenylalanine at position 8, and hydrophilic amino acids at position 1. Out of 20 novel analogues tested for long duration position 8, and hydrophilic amino acids at position 1. Out of 20 novel analogues tested for long duration of action in this series, only seven ([Ac-DNal(1),DCpa(2),DPal(3),Aph(5),DAph(6),ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa(2),DPal(3), Aph(5)(For),DAph(6)(For), ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Ac),DAph(6)(Ac),- ILys(8),DAla(10)]GnRH (acyline), [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Pio),DAph(6)(Pio),ILys(8,)DAla(10)]GnRh, [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Ac),ILys(8),DAla(10)]GnRH, [Ac-DNalDCpa(2),DPal(3),Aph(5)(Atz-beta Ala),DAph(6)(Atz- beta Ala),ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa2,DPal(3),Aph(5)(Atz-Gab),DAph(6)(Atz-Gab),ILys(8),DAla(10)]GnRH) had relative potencies and/or duration of action comparable to those of azaline B. The others were one-half to one-tenth as effective as azaline B. N-alpha-Methylated backbone substitutions at position 5 yielded analogues that were significantly more hydrophilic presumably because of the breakage of the NH alpha-Tyr(5) to Arg(8)-CO hydrogen bond reported to stabilize a beta-turn encompassing residues 5-8 and which favored beta-sheet formation as shown earlier by Haviv et al.(2) This substitution resulted, however, in an increased potency in the histamine release assay and in significantly shorter duration of action.(3) Similarly, attempts at replacing isopropyllysine in position 8 by either isopropyl-4-aminophenylalanine or isopropyl-4(aminomethyl)phenylalanine resulted in loss of potency in the AOA.Changes in chirality at position 1 or 10 resulted in analogues that were one-tenth and one-half as potent, respectively, as acyline. Introduction of a relatively hydrophilic acetylated residue in position 1 (Ac-4-aminophenylalanine, Ac-2-quinolylalanine, Ac-3-quinolylalanine) also resulted in potent analogues in the AOA in the latter two cases (yet very short acting in the case of ([Ac-D2Qal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Atz),ILys(8),DAla(10)]-GnRH). Introduction of either mesityl, (2-chlorophenyl)isourea, or (3-chlorophenyl)isourea as a substituent on the 4-amino function at residues 5 and 6 of the azaline B precursor was considerably less successful. In this article, we describe in details, improved synthetic protocols for all novel amino acis, N alpha-methylation of amino acids on the resin, and elimination of the undesired N omega-methylation of pyridylalanine at position 3 as the result of base treatment (piperidine or hydrazine) during the deprotection of the Fmoc group or formation of the triazole moiety in the presence of CH2Cl2.
    DOI:
    10.1021/jm00014a017
  • 作为产物:
    描述:
    间硝基氯化苄盐酸sodium hydroxide氯化亚砜sodium ethanolate 作用下, 以 叔丁醇 为溶剂, 反应 49.5h, 生成 N-叔丁氧羰基-D-3-硝基苯丙氨酸
    参考文献:
    名称:
    Gonadotropin-Releasing Hormone Antagonists: Novel Members of the Azaline B Family
    摘要:
    A series of antagonists of gonadotropin-releasing hormone (GnRH) homologous to azaline B ([Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Atz),ILys(8),DAla(10)]GnRH) was synthesized, characterized, and tested in a rat antiovulatory assay (AOA). Selected analogues were also tested in both an in vitro dispersed rat pituitary cell culture assay for inhibition of GnRH-stimulated luteinizing hormone release and an in. vitro histamine release assay. The duration of action of some of the most potent and safest analogues in those assays was also determined in the castrated male rat in order to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone release. Structurally, this series of analogues has novel substitutions (X and Y) in the structure of the azaline B precursor: [Ac-DNal(1),DCpa(2),DPal(3),-Aph(5)(X),DAph(6)(Y),ILys(8),DAla(10)]GnRH. These substitutions were designed to confer increased hydrophilicity as compared to that of azaline B (determined by relative retention times on a C-18 reverse phase column using a triethylammonium phosphate buffer at pH 7.3) or to make them more easily accessible synthetically. Some bulky substituents were introduced in order to probe the spatial limitations of the receptor's cavity. These substitutions include acylated 4-aminophenylalanine at positions 5 and/or 6 (29 analogues), N-alpha-methylated backbone substitutions (six analogues), N-omega-isopropylaminophenylalanine at position 8, and hydrophilic amino acids at position 1. Out of 20 novel analogues tested for long duration position 8, and hydrophilic amino acids at position 1. Out of 20 novel analogues tested for long duration of action in this series, only seven ([Ac-DNal(1),DCpa(2),DPal(3),Aph(5),DAph(6),ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa(2),DPal(3), Aph(5)(For),DAph(6)(For), ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Ac),DAph(6)(Ac),- ILys(8),DAla(10)]GnRH (acyline), [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Pio),DAph(6)(Pio),ILys(8,)DAla(10)]GnRh, [Ac-DNal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Ac),ILys(8),DAla(10)]GnRH, [Ac-DNalDCpa(2),DPal(3),Aph(5)(Atz-beta Ala),DAph(6)(Atz- beta Ala),ILys(8),DAla(10)]GnRH, [Ac-DNal(1),DCpa2,DPal(3),Aph(5)(Atz-Gab),DAph(6)(Atz-Gab),ILys(8),DAla(10)]GnRH) had relative potencies and/or duration of action comparable to those of azaline B. The others were one-half to one-tenth as effective as azaline B. N-alpha-Methylated backbone substitutions at position 5 yielded analogues that were significantly more hydrophilic presumably because of the breakage of the NH alpha-Tyr(5) to Arg(8)-CO hydrogen bond reported to stabilize a beta-turn encompassing residues 5-8 and which favored beta-sheet formation as shown earlier by Haviv et al.(2) This substitution resulted, however, in an increased potency in the histamine release assay and in significantly shorter duration of action.(3) Similarly, attempts at replacing isopropyllysine in position 8 by either isopropyl-4-aminophenylalanine or isopropyl-4(aminomethyl)phenylalanine resulted in loss of potency in the AOA.Changes in chirality at position 1 or 10 resulted in analogues that were one-tenth and one-half as potent, respectively, as acyline. Introduction of a relatively hydrophilic acetylated residue in position 1 (Ac-4-aminophenylalanine, Ac-2-quinolylalanine, Ac-3-quinolylalanine) also resulted in potent analogues in the AOA in the latter two cases (yet very short acting in the case of ([Ac-D2Qal(1),DCpa(2),DPal(3),Aph(5)(Atz),DAph(6)(Atz),ILys(8),DAla(10)]-GnRH). Introduction of either mesityl, (2-chlorophenyl)isourea, or (3-chlorophenyl)isourea as a substituent on the 4-amino function at residues 5 and 6 of the azaline B precursor was considerably less successful. In this article, we describe in details, improved synthetic protocols for all novel amino acis, N alpha-methylation of amino acids on the resin, and elimination of the undesired N omega-methylation of pyridylalanine at position 3 as the result of base treatment (piperidine or hydrazine) during the deprotection of the Fmoc group or formation of the triazole moiety in the presence of CH2Cl2.
    DOI:
    10.1021/jm00014a017
点击查看最新优质反应信息

文献信息

  • Synthesis and Evaluation of Vancomycin Aglycon Analogues That Bear Modifications in the N-Terminal <scp>d</scp>-Leucyl Amino Acid
    作者:Christine M. Crane、Dale L. Boger
    DOI:10.1021/jm801549b
    日期:2009.3.12
    The synthesis and biological evaluation of a series of vancomycin aglycon analogues bearing alternative residue 1 N-methyl-d-amino acids are described. The analogues were prepared to define whether H-bonding d-amino acids could improve the affinity for the model ligands N,N′-Ac2-l-Lys-d-Ala-d-Ala (2) and N,N′-Ac2-l-Lys-d-Ala-d-Lac (3) and improve antimicrobial activity against vancomycin-sensitive
    轴承替代残基1的一系列的万古霉素糖苷配基类似物的合成和生物学评价Ñ甲基d α-氨基酸中有描述。制备类似物以确定 H 键合d -氨基酸是否可以提高对模型配体N , N '-Ac 2 - l -Lys- d -Ala- d -Ala ( 2 ) 和N , N '-的亲和力Ac 2 - l -Lys- d -Ala- d -Lac ( 3) 并提高对万古霉素敏感或耐万古霉素细菌的抗菌活性。此外,一系列具有上的残留物1所附的亲核试剂(和胺)类似物的d α-氨基酸中描述检查它们与的C-末端酯反应的能力的是3,形成一个共价连接升-Lys- d -Ala 到天然产物类似物。
  • Semisynthesis of a Bacterium with Non-canonical Cell-Wall Cross-Links
    作者:David A. Dik、Nan Zhang、Jason S. Chen、Bill Webb、Peter G. Schultz
    DOI:10.1021/jacs.0c02956
    日期:2020.6.24
    The cell wall is an elaborate framework of peptidoglycan that serves to protect the bacterium against osmotic challenge. This exoskeleton is composed of repeating saccharides covalently cross-linked by peptide stems. The general structure of the cell wall is widely conserved across diverse Gram-negative bacteria. To begin to explore the biological consequence of introducing non-canonical cross-links into the cell wall of Escherichia coli, we generated a bacterium where up to 31% of the cell-wall cross-links are formed by a non-enzymatic reaction between a sulfonyl fluoride and an amino group. Bacteria with these noncanonical cell-wall cross-links achieve a high optical density in culture, divide and elongate successfully, and display no loss of outer membrane integrity. This work represents a first step in the design of bacteria with non-canonical "synthetic" cell walls.
  • PROCÉDÉ DE PRÉPARATION D'ACIDES AMINES CHIRAUX
    申请人:Diverchim
    公开号:EP2655322A1
    公开(公告)日:2013-10-30
  • METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS
    申请人:THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRCULTURAL L RESEARCH ORGANIZA
    公开号:US20190246639A1
    公开(公告)日:2019-08-15
    A method of controlling a fungus infection in a plant susceptible to Botrytis infection is provided. The method comprising applying to the plant an effective amount of a phenylalanine or an analog thereof for controlling said fungus infection in the plant.
  • METHOD OF IMPROVING PLANT PERFORMANCE
    申请人:The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization
    公开号:US20200383327A1
    公开(公告)日:2020-12-10
    Provided composition and methods for controlling, treating or preventing a pathogenic infection in a plant with a phenylalanine solution. The plant may be at a post-harvest and/or at a pre-harvest stage.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸